|
Jun 18
|
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
May 11
|
Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results
|
|
May 10
|
Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts
|
|
May 9
|
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Regenxbio Inc Earnings Call
|
|
May 9
|
Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...
|
|
May 8
|
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 8
|
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
May 1
|
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
Apr 24
|
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
|
Apr 17
|
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Mar 28
|
REGENXBIO Sees Positive Results For Macular Degeneration Therapy
|
|
Mar 28
|
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
|
|
Mar 27
|
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
|
|
Mar 18
|
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
|
|
Mar 13
|
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
|
|
Mar 11
|
REGENXBIO to Participate in Upcoming Investor Conferences
|
|
Mar 8
|
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
|
|
Mar 7
|
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates
|